OBJECTIVES: To determine the association between poison center opioid exposure calls and National Vital Statistics System (NVSS) deaths. METHODS: We categorized Centers for Disease Control and Prevention NVSS mortality and the Researched Abuse, Diversion and Addiction-Related Surveillance System poison center program cases from 2006 to 2016 by International Classification of Diseases, Tenth Revision, codes (heroin [T40.1]; natural or semisynthetic opioids [T40.2]; methadone [T40.3]; synthetic opioids, other than methadone [T40.4]). We scaled rates by 100 000 population and calculated Pearson correlation coefficients. Sensitivity analysis excluded polysubstance cases involving either heroin or synthetic opioids as well as natural and semisynthetic opioids. RESULTS: The NVSS mortality and poison center program exposure rates showed similar trends from 2006 to 2012, and diverged after 2012 for all opioids combined, natural and semisynthetic opioids, and synthetic opioids (r = -0.37, -0.12, and 0.30, respectively). Sensitivity analysis with removal of heroin or synthetic opioid polysubstance deaths markedly improved correlations for all opioids combined and natural and semisynthetic opioids (r = 0.87 and 0.36, respectively). CONCLUSIONS: The NVSS mortality and poison center exposure rates showed similar trends from 2006 to 2012 then diverged, with sensitivity analysis suggesting polysubstance cases also involving heroin or illicit fentanyl as the cause. Public Health Implications. The NVSS and poison center program may provide complementary data when trends diverge. Public health interventions must include both licit and illicit opioids for maximal impact.
OBJECTIVES: To determine the association between poison center opioid exposure calls and National Vital Statistics System (NVSS) deaths. METHODS: We categorized Centers for Disease Control and Prevention NVSS mortality and the Researched Abuse, Diversion and Addiction-Related Surveillance System poison center program cases from 2006 to 2016 by International Classification of Diseases, Tenth Revision, codes (heroin [T40.1]; natural or semisynthetic opioids [T40.2]; methadone [T40.3]; synthetic opioids, other than methadone [T40.4]). We scaled rates by 100 000 population and calculated Pearson correlation coefficients. Sensitivity analysis excluded polysubstance cases involving either heroin or synthetic opioids as well as natural and semisynthetic opioids. RESULTS: The NVSS mortality and poison center program exposure rates showed similar trends from 2006 to 2012, and diverged after 2012 for all opioids combined, natural and semisynthetic opioids, and synthetic opioids (r = -0.37, -0.12, and 0.30, respectively). Sensitivity analysis with removal of heroin or synthetic opioid polysubstance deaths markedly improved correlations for all opioids combined and natural and semisynthetic opioids (r = 0.87 and 0.36, respectively). CONCLUSIONS: The NVSS mortality and poison center exposure rates showed similar trends from 2006 to 2012 then diverged, with sensitivity analysis suggesting polysubstance cases also involving heroin or illicit fentanyl as the cause. Public Health Implications. The NVSS and poison center program may provide complementary data when trends diverge. Public health interventions must include both licit and illicit opioids for maximal impact.
Authors: Jonathan M Davis; Stevan G Severtson; Becki Bucher-Bartelson; Richard C Dart Journal: Pharmacoepidemiol Drug Saf Date: 2013-10-16 Impact factor: 2.890
Authors: Becki Bucher Bartelson; M Claire Le Lait; Jody L Green; M Soledad Cepeda; Paul M Coplan; Jean-Yves Maziere; Gregory P Wedin; Richard C Dart Journal: Pharmacoepidemiol Drug Saf Date: 2017-07-31 Impact factor: 2.890
Authors: Alvin C Bronstein; Daniel A Spyker; Louis R Cantilena; Jody L Green; Barry H Rumack; Sandra L Giffin Journal: Clin Toxicol (Phila) Date: 2009-12 Impact factor: 4.467
Authors: Deborah M Stone; Kristin M Holland; Brad Bartholow; Joseph E Logan; Wendy LiKamWa McIntosh; Aimee Trudeau; Ian R H Rockett Journal: Am J Public Health Date: 2017-06-22 Impact factor: 9.308
Authors: Patricia Eckardt; Donald Bailey; Holli A DeVon; Cynthia Dougherty; Pamela Ginex; Cheryl A Krause-Parello; Rita H Pickler; Therese S Richmond; Eleanor Rivera; Carol F Roye; Nancy Redeker Journal: Nurs Outlook Date: 2020-04-09 Impact factor: 3.250
Authors: Celeste A Mallama; James P Trinidad; Richard S Swain; Yueqin Zhao; Corinne Woods; Jana K McAninch Journal: Pharmacoepidemiol Drug Saf Date: 2019-08-11 Impact factor: 2.890
Authors: Maia Terashvili; Bhavana Talluri; Watchareepohn Palangmonthip; Kenneth A Iczkowski; Patrick Sanvanson; Bidyut K Medda; Banani Banerjee; Christopher W Cunningham; Jyoti N Sengupta Journal: Neuropharmacology Date: 2021-07-10 Impact factor: 5.273
Authors: Stevan Geoffrey Severtson; Scott E D Kreider; Elise C Amioka; Zachary R Margolin; Janetta L Iwanicki; Richard C Dart Journal: Pain Med Date: 2020-12-25 Impact factor: 3.750